Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Mesothelioma, Malignant 1

Interventions

pembrolizumab 110Specimen Handling 79Magnetic Resonance Spectroscopy 70Carboplatin 67Cisplatin 66Biopsy 57Nivolumab 56Radiotherapy 50Cyclophosphamide 50Paclitaxel 48durvalumab 38Radiation 37Gemcitabine 37olaparib 32Rituximab 32Etoposide 32Dexamethasone 32Doxorubicin 30Docetaxel 30atezolizumab 28Lenalidomide 27Ipilimumab 27Taxes 26Pemetrexed 25Bevacizumab 25Vincristine 24Cytarabine 24Prednisone 23Platinum 23Radiotherapy, Intensity-Modulated 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × anetumab ravtansine × 90 days × Clear all
NCT03126630 2026-04-01

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
49 enrolled 20 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡